Home Biosimilar Antibodies Immunology & Inflammation PD-1/PD-L1 Spartalizumab (anti-PD-1)
For research use only. Not for use in humans.

Spartalizumab (anti-PD-1)

Synonyms: PDR001

Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.

Spartalizumab (anti-PD-1)

Click to purchase the isotype control of Spartalizumab (anti-PD-1)

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99.0% Protein concentration: 5.0 mg/ml Endotoxin Level: ≤1 EU/mg
99.0

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 14
BMS-1 13
BMS-202 28
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 5
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.
Features
Human IgG4
Targets/IC50/Ki
PD-1
In vivo
In phase 1/2 studies, PDR001 has a manageable safety profile and preliminary antitumor activity in advanced solid tumors.
References

Product Details

CAS No. 1935694-88-4
Isotype Human IgG4
Source CHO cells
Sterility 0.2 μM filtered
Formulation PBS buffer, pH 7.2
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07567469 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Cemiplimab+Fianlimab Fixed Dose Combi High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma Regeneron Pharmaceuticals 2026-08-31 PHASE1; PHASE2
NCT06794775 RECRUITING Drug: Nivolumab|Drug: Nivolumab + Ipilimumab Malignant Melanoma Stage III Hildur Helgadottir 2025-07-10 PHASE3
NCT06264180 RECRUITING Drug: Single-agent chemotherapy Advanced Melanoma Replimune, Inc. 2024-07-11 PHASE3
NCT07762703 NOT_YET_RECRUITING Drug: BreakVax|Drug: Ipilimumab 2.5 mg|Drug: Pembrolizumab|D Triple-Negative Breast Cancer (TNBC) BreakBio Corp 2026-09 PHASE1; PHASE2
NCT06731413 RECRUITING Drug: Reduced Dose of Chemotherapy and Immunotherapy Non-Small Cell Lung Cancer; NSCLC; Advanced Non-Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer Virginia Commonwealth University 2025-02-11 PHASE2
NCT04058756 ACTIVE_NOT_RECRUITING Drug: PDR001 Advanced Solid Tumors Novartis Pharmaceuticals 2019-10-30 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-05-05)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.